Search

Midostaurin

It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.

Technetium Tc-99m medronate

Like other bisphosphonates used in the treatment of osteoporosis, medronic acid binds to the hydroxyapatite crystals within bone, and in this way localizes the drug to bone for delineation of areas of … Technetium (99mTc) medronic acid is a pharmaceutical product used in nuclear medicine imaging. It is composed of a technetium ion complexed with medronic acid, a type of bisphosphonate.

Mogamulizumab

[L4168] It was approved for the same indications in Canada in June 2022. … [L4170] On August 8 2018, the U.S.

XMT-1001

XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models … In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal).

Iobitridol

Iobitridol has been used in trials studying the diagnostic of Diagnostic Imaging, Coronary Artery Disease, Type 2 Diabetes Mellitus, and Coronary Atherosclerosis.

Ocrelizumab

It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada. … In clinical trials of patients with relapsing forms of MS, treatment with ocrelizumab resulted in reduced relapse rates and reduced worsening of disability compared to [interferon beta-1a].

Vaborbactam

[A32053] It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. … Vaborbactam is a β-lactamase inhibitor based on a cyclic boronic acid pharmacophore.

Plinabulin

Sampatrilat

Sampatrilat has a monoisotopic molecular weight of 584.25 Da.

Ribociclib

Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.